Lilly/BI Gain Japan Approval For First Lantus Biosimilar
This article was originally published in PharmAsia News
Lilly and Boehringer Ingelheim have confirmed that they have received regulatory approval in Japan for their insulin glargine product as the first biosimilar version of Sanofi's Lantus, the first such local competition for the branded basal insulin analog.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.